Hoodia, a case study
1963-2008

November 2008

Dr Vinesh Maharaj
Research Group Leader
CSIR, Biosciences
Hoodia Development Cycle

Discovery

Development: Clinical and regulatory approval

Commercial Sales

Cumulative Investment

Hit → Lead → Preclinical

CSIR

Time

CSIR
What is Hoodia?

Hoodia is a novel method of weight management derived from the Hoodia plant

• Based on formulations invented by CSIR
  • processed herbal extracts
  • purified chemical compounds or analogues thereof
  • synthetic or natural
Hoodia: History of use

• Hoodia research was stimulated by traditional use of plant by San people

• Used by San people as substitute for food and water (Marloth, 1932: White and Sloan, 1937)

• Has an insipid taste and used to quench thirst (Pappe, 1862)
Hoodia:
Early Research
1963-1971

- NFRI of CSIR launched a project to investigate food from the “veld”
- Nutritional value and long term toxicity studies was the focus of study
- Hoodia was one of several 100 plants
- Prepared several extracts of the plant
- Extracts tested in rodents
- Appetite suppressant properties with weight loss
- No apparent side effects
- Data kept confidential
Hoodia: Early Research

1983-1986

• Active isolated through bioassay guided fractionation
• Fractions tested in vivo
• Innovation made possible by acquisition of world-class instrumentation for structure elucidation
Biological assaying

Food consumption

Dosage on days 1, 2, 3 given in mg/kg/day

Biological assaying

Food consumption: Active vs fenfluramine

Dosage on days 1, 2, 3 given in mg/kg/day
- Active: 30 mg/kg
- Fenfluramine: 15 mg/kg
Hoodia: Innovations

1990-1997

• Additional studies
  • Acute in vivo toxicity
  • Attempted synthesis
  • Efficacy confirmed in independent labs
  • Cultivation of plants with confirmation of active in plant extracts
• New formulation for obesity control invented and patented
Hoodia Development Cycle

Discovery

Development: Clinical and regulatory approval

Commercial Sales

Cumulative Investment

Hit → Lead → Preclinical

CSIR

CSIR/Phytopharm

Time
Hoodia: Further development

• CSIR licensed patent to Phytopharm plc in UK
• CSIR/Phytopharm joint research programme focused on:
  • GMP manufacturing
  • Quality control
  • Safety and efficacy
Hoodia: Manufacturing

- Botanical and Clinical Supplies Unit for the manufacture herbal extracts
- Manufacture extracts in compliance with GMP
- Material approved for clinical trials
Hoodia: Quality Control

- HPLC method developed for the quantitative analysis of steroid glycosides
- HPLC MS used to confirm the compounds
- Method applied to the analysis of steroid glycosides in a range of samples
Hoodia: Safety and efficacy

• Obtained preclinical data
  • Acute and chronic *in vivo* toxicology studies
  • pK data obtained
  • *In vitro* toxicology, metabolism
  • *In vivo* efficacy, 2 animal species
Hoodia Development Cycle

- **Discovery**
  - Hit
  - Lead
  - Preclinical

- **Development: Clinical and regulatory approval**

- **Commercial Sales**

**Cumulative Investment**

- **CSIR**
- **CSIR/Phytopharm**
- **Multinational**

**Time**

© CSIR 2006  www.csir.co.za
Hoodia: Further development

• Phytopharm further on licensed to Pfizer for further development and commercialization

• Completed early clinical studies

• Pfizer discontinued clinical development
Hoodia: Further development

• Phytopharm sub-licensed to Unilever
  • Currently in development as a food ingredient for weight management
  • Safety and clinical studies on-going
  • Establishing a supply chain for product
  • Expect a commercial product in 2-3 years
Hoodia cultivation—Supply Chain

[Images of Hoodia cultivation and supply chain process]
Indigenous Knowledge & the CSIR/San Agreement

“..San people are custodians of an ancient body of traditional knowledge …related inter alia to human uses of the Hoodia plant …”

“The CSIR acknowledges the existence and the importance of the traditional knowledge of the San people, and the fact that such body of knowledge, existing for millennia, predated scientific knowledge developed…”
CSIR/San Agreement: Numbers

CSIR and San agreed for CSIR to pay eight percent of all milestone payments it receives from its licensee, UK-based Phytopharm plc, as well as six percent of all royalties that the CSIR receives once the drug is commercially available.

Potential income into a San Hoodia Benefit Sharing Trust Trustees include:

- SA Department of Science and Technology
- CSIR
- San Representatives (≠ Khomani, !Xun, Khwe)
- Other San in the southern African region
- Working Group of Indigenous Minorities in Southern Africa
Hoodia Licensing: Benefits to SA

- Full involvement of South African scientists in development
- Transfer of state-of-the-art phyto-medicine production technology to South Africa

- Potential royalty revenue through licensing of patented technology; milestone payments linked to clinical trials
- Global recognition of SA’s innovation capacity
- Agroprocessing businesses established in SA for both commercial and community farmers
## Summary of events

<table>
<thead>
<tr>
<th>Year</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1963</td>
<td>CSIR includes <em>Hoodia</em> in research project on edible plants, based on ethnobotany</td>
</tr>
<tr>
<td>1971</td>
<td><em>Hoodia</em> project mothballed, insurmountable technical problems</td>
</tr>
<tr>
<td>1983-1986</td>
<td>Technological advances. Scientific breakthrough at CSIR leads to discovery of active ingredient in <em>Hoodia</em>.</td>
</tr>
<tr>
<td>1986-1996</td>
<td>CSIR continues development of <em>Hoodia</em>, files world-wide patents to protect its invention of novel method of obesity control.</td>
</tr>
<tr>
<td>1997</td>
<td>CSIR licenses Phytopharm for further development of Hoodia</td>
</tr>
<tr>
<td>1998</td>
<td>CSIR publishes its Bioprospecting Policy, guaranteeing sharing of benefits with owners of Indigenous Knowledge</td>
</tr>
<tr>
<td>1998</td>
<td>Phytopharm sub-licenses Pfizer to complete Hoodia clinical development, obtain regulatory approval and commercialize</td>
</tr>
</tbody>
</table>
## Summary of events cont…..

<table>
<thead>
<tr>
<th>Year</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1999</td>
<td>CSIR signs historical bioprospecting agreement with South African Traditional Healers, invited by UN to present details at Lyon Summit on Trade and Development</td>
</tr>
<tr>
<td>2001</td>
<td>UK newspaper reporter questions CSIR-Phytopharm-Pfizer collaboration, without involvement of San</td>
</tr>
<tr>
<td>2002-2003</td>
<td>CSIR and San meet regularly to share Hoodia information; involve independent experts in workshops; negotiate benefit sharing agreement</td>
</tr>
<tr>
<td>24 March 2003</td>
<td>CSIR and San sign Hoodia benefit sharing agreement</td>
</tr>
<tr>
<td>2003</td>
<td>Pfizer discontinues clinical development</td>
</tr>
<tr>
<td>2004</td>
<td>Phytopharm sub licenses Unilever to continue development</td>
</tr>
<tr>
<td>Today</td>
<td>Hoodia being developed as a food ingredient for weight management</td>
</tr>
</tbody>
</table>